Phosphatase Inhibitor Screening via Regulatory Subunit Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a systematic approach to selectively inhibit phosphatases, particularly serine/threonine phosphatases, due to their oligomeric nature, intrinsically disordered regulatory subunits, and limited structural information, making it difficult to develop selective and allosteric inhibitors.
Innovation Solution
A method involving an assay to screen test compounds for selective binding to holophosphatases by immobilizing and comparing binding affinities to different holophosphatases, using surface plasmon resonance and affinity capture techniques, to identify compounds that bind selectively to regulatory subunits, and validate their inhibitory activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If catalytic subunits of phosphatases are targeted for inhibition, then phosphatase activity is inhibited, but selectivity is lost due to promiscuity of catalytic subunits across multiple holophosphatases
Solution Approach 1:
The patent segments the holophosphatase into catalytic subunit and regulatory subunit components. By targeting the regulatory subunit-specific region rather than the shared catalytic subunit, the invention achieves selectivity for specific holophosphatases while maintaining inhibitory activity. This segmentation allows differentiation between multiple phosphatases that share common catalytic components.
Solution Approach 2:
The invention focuses inhibition on a specific local region - the regulatory subunit interface or regulatory subunit-specific domain - rather than the entire catalytic site. This localized targeting approach enables selective inhibition of particular holophosphatases by exploiting unique structural features of individual regulatory subunits while leaving other phosphatases unaffected.
2Adaptability or versatility
If regulatory subunits are used for selective inhibition, then selectivity is improved, but stability and expressibility deteriorate due to intrinsically disordered nature
Solution Approach 1:
The patent performs preliminary structural characterization of the regulatory subunit-catalytic subunit interface before drug design. By pre-identifying stable structural elements, binding pockets, or conformational features of the regulatory subunit through structural biology methods, the invention creates a stable foundation for selective drug targeting despite the intrinsically disordered nature of regulatory subunits.
Solution Approach 2:
The invention uses the catalytic subunit as an intermediary to target the regulatory subunit. Instead of directly targeting the unstable regulatory subunit, the drug binds to the catalytic subunit-regulatory subunit interface or uses the catalytic subunit as a delivery vehicle, thereby indirectly achieving regulatory subunit specificity while benefiting from the stability of the catalytic subunit structure.
3Adaptability or versatility
If structure-based drug design is applied to holophosphatases, then selectivity can be improved, but availability of structural information is limited due to few crystallized holophosphatases
Solution Approach 1:
The patent applies structure-based drug design principles universally across multiple holophosphatases by identifying conserved structural features and interface motifs. By developing a generalizable structural framework that can be applied to different phosphatase families, the invention overcomes the limitation of having only a few crystallized structures while still achieving selectivity through family-specific structural variations.
Solution Approach 2:
The invention creates structural models or homology models of uncrystallized holophosphatases based on available crystal structures. By copying and adapting known structural features to predict the structure of related but uncharacterized phosphatases, the invention generates sufficient structural information for selective drug design without requiring physical crystallization of each target.
4Productivity
If enzymatic assays with artificial substrates are used, then catalytic activity can be measured, but selectivity is lost due to discovery of non-selective catalytic inhibitors
Solution Approach 1:
The patent introduces a selective binding intermediary - such as a regulatory subunit-specific peptide, antibody, or small molecule - that precedes the enzymatic assay. This intermediary selectively binds to or stabilizes the specific holophosphatase of interest, allowing subsequent measurement of catalytic activity only for that selected enzyme, thereby separating the selectivity step from the productivity-measuring enzymatic step.
Solution Approach 2:
The invention segments the assay into two distinct steps: first, selective binding/recognition of the target holophosphatase using regulatory subunit-specific reagents, and second, measurement of catalytic activity using artificial substrates. This segmentation allows the first step to provide selectivity while the second step provides productivity, with the overall assay achieving both goals through sequential operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of selective and allosteric inhibitors of phosphatases, overcoming the challenges of promiscuity and stability issues with regulatory subunits, and providing a therapeutic potential for diseases associated with protein misfolding stress.
Implementation Method 1
using surface plasmon resonance and affinity capture techniques
Data Source
AI summary
The present invention discloses a method to discover selective inhibitors of phosphatases. Thus the invention provides a method for screening a test compound to determine whether the compound binds a holophosphatase selectively or non-selectively comprising: i) providing a first holophosphatase wherein said holophosphatase is captured/immobilised; ii) testing a test compound for its ability to bind to the first holophosphatase; iii) providing a second holophosphatase wherein said second holophosphatase is captured/immobilised; iv) testing the same test compound for its ability to bind to the second holophosphatase; v) comparing the binding of the test compound to said first holophosphatase with the binding to said second phosphatase wherein a compound that binds a holophosphatase selectively will bind to said first holophosphatase but not said second holophosphatase; or will bind to said second holophosphatase but not said first; or wherein a compound that binds a holophosphatase non-selectively will bind to both said first holophosphatase and said second holophosphatase.